3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Sarcoma
4
Sarcoma, Ewing
3
Neoplasms
3
Stomach Neoplasms
1
Neuroendocrine Tumors
1
Mesothelioma
1
Leiomyosarcoma
1
Glioblastoma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Endometrial Neoplasms
1
Desmoplastic Small Round Cell Tumor
1
Colorectal Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Interventions
Doxorubicin
25
Gemcitabine
16
Trabectedin
12
Ifosfamide
12
Radiotherapy
11
Docetaxel
10
Dacarbazine
8
pazopanib
7
Nivolumab
6
Specimen Handling
5
Biopsy
5
liposomal doxorubicin
4
Temozolomide
4
pembrolizumab
3
Sunitinib
3
Sorafenib
3
Radiation
3
Magnetic Resonance Spectroscopy
3
Filgrastim
3
rucaparib
2
pegfilgrastim
2
olaratumab
2
eribulin
2
durvalumab
2
cixutumumab
2
cemiplimab
2
brostallicin
2
belinostat
2
avelumab
2
X-Rays
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leiomyosarcoma
×
PM 01183
×
Sarcoma
×
Clear all
NCT06088290
2026-05-15
SaLuDo
PharmaMar
Phase 3
Active not recruiting
455 enrolled